In the present study, we show for the first time that obatoclax, a pan-Bcl-2 inhibitor, promotes differentiation of human AML HL-60 cells accompanied by cell cycle arrest and the down-regulation of Bcl-2 protein levels. This evidence concerns the gene BCL2 and acute myeloid leukemia.